Matches in SemOpenAlex for { <https://semopenalex.org/work/W70976452> ?p ?o ?g. }
- W70976452 endingPage "70" @default.
- W70976452 startingPage "70" @default.
- W70976452 abstract "Abstract Introduction Novel approaches are needed to treat pediatric relapsed/refractory B-cell precursor acute lymphoblastic leukemia (BCP-ALL). Blinatumomab is a bispecific T-cell engager (BiTE®) antibody that has shown remission in an exploratory study of 36 adult patients with relapsed/refractory ALL. Primary toxicities in adults have been cytokine release syndrome (CRS) and central nervous system (CNS) related toxicity. We initiated a phase 1/2 multicenter study to identify, in the phase 1 part, the optimal dose of blinatumomab in pediatric patients with relapsed/refractory BCP-ALL. Methods In this ongoing study, eligible patients are <18 years old and must have BCP-ALL that is refractory, in second or later bone marrow relapse, or in any marrow relapse after allogeneic hematopoietic stem cell transplantation (HSCT). Blinatumomab is administered by continuous intravenous infusion over 28 days, followed by a 14-day treatment-free interval (up to five cycles). Data from the five doses that have been explored to date are presented. Maximum tolerated dose (MTD), defined as the highest dose level with less than two of six patients experiencing dose-limiting toxicity (DLT) within the first treatment cycle, is the primary endpoint in the phase 1 part of the study (rolling 6 design). Serum samples were collected for pharmacokinetics evaluation and cytokine measurement. Results In the phase 1 part of the study, 34 patients received a total of 56 cycles. Six (18%) patients had refractory disease and 6 (18%) had experienced at least two bone marrow relapses. Twenty-two (65%) patients had relapsed following HSCT. DLTs for dose levels 1 through 4 are summarized in the Table. The MTD for this patient population was established at 15 µg/m²/day. In order to reduce the risk of CRS, a dose of 5 µg/m²/day for 7 days escalating to 15 µg/m²/day for the remainder of the first cycle and all following cycles (5→15 µg/m²/day; dose level 5) was evaluated as recommended dose. None of the 11 patients treated at this dose level developed CRS and no grade 3 CNS-related adverse events (AEs) occurred. Across dose levels, the most common AEs regardless of causality were pyrexia (62% of patients), headache (35%), anemia (29%), and hypertension (29%). One patient treated at 5 µg/m²/day had a grade 3 seizure at the beginning of the second treatment cycle, which resolved clinically and showed no changes on MRI. Across all dose levels, 11 (32%) patients had complete remission (CR), one (3%) had hypocellular blast-free bone marrow, and two (6%) had partial remission within the first two treatment cycles, for an overall response rate of 41%. Some efficacy assessments are still ongoing, and full response data for the phase 1 part of the study will be available at the time of presentation. Two patients experienced hematologic relapse (one each at dose levels 2 and 3, during the fifth and third cycles, respectively). Pharmacokinetic parameters, such as steady-state concentration (Css) and clearance, appeared to be similar to those from adult patients with relapsed/refractory BCP-ALL who received body surface area-based blinatumomab dosing. Transient elevations of serum cytokines were observed mainly in the first two days after infusion start, in particular IL-6, IFN-gamma, IL-10, and, to a lesser extent, IL-2 and TNF-α. Conclusions In the ongoing phase 1 part of this study in pediatric patients with relapsed/refractory BCP-ALL, a dose of 15 µg/m²/day was established as MTD. Cytokine-release syndrome has been dose-limiting. Pharmacokinetic analysis at the recommended dose of 5→15 µg/m²/day is ongoing. This dose de-escalation strategy has been successful in ameliorating severe CRS to date. Blinatumomab treatment has shown promising antitumor activity in this relapsed/refractory patient population. Disclosures: von Stackelberg: Amgen Inc.: Honoraria. Zugmaier:Amgen Research (Munich) GmbH: Employment; Amgen Inc.: Equity Ownership. Rheingold:Novartis: Research Funding. Holland:Amgen Inc.: Employment; Amgen Inc.: Equity Ownership. Mergen:Amgen Research (Munich) GmbH: Employment; Amgen Inc.: Equity Ownership. Fischer:Amgen Research (Munich) GmbH: Employment; Amgen Inc.: Equity Ownership. Zhu:Amgen Inc.: Employment; Amgen Inc.: Equity Ownership. Hijazi:Amgen Research (Munich) GmbH: Employment; Amgen Inc.: Equity Ownership. Gore:Amgen Inc.: Travel expenses paid for DSMC meeting (Feb 2013) Other." @default.
- W70976452 created "2016-06-24" @default.
- W70976452 creator A5001066329 @default.
- W70976452 creator A5011806164 @default.
- W70976452 creator A5018621362 @default.
- W70976452 creator A5022712318 @default.
- W70976452 creator A5024202047 @default.
- W70976452 creator A5028056789 @default.
- W70976452 creator A5029816641 @default.
- W70976452 creator A5030393361 @default.
- W70976452 creator A5032050812 @default.
- W70976452 creator A5035626095 @default.
- W70976452 creator A5037169725 @default.
- W70976452 creator A5038841996 @default.
- W70976452 creator A5040001760 @default.
- W70976452 creator A5057678079 @default.
- W70976452 creator A5067126589 @default.
- W70976452 creator A5073947547 @default.
- W70976452 creator A5076109830 @default.
- W70976452 creator A5084414168 @default.
- W70976452 creator A5085057434 @default.
- W70976452 creator A5085264071 @default.
- W70976452 creator A5086181841 @default.
- W70976452 date "2013-11-15" @default.
- W70976452 modified "2023-10-18" @default.
- W70976452 title "A Phase 1/2 Study Of Blinatumomab In Pediatric Patients With Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia" @default.
- W70976452 doi "https://doi.org/10.1182/blood.v122.21.70.70" @default.
- W70976452 hasPublicationYear "2013" @default.
- W70976452 type Work @default.
- W70976452 sameAs 70976452 @default.
- W70976452 citedByCount "20" @default.
- W70976452 countsByYear W709764522014 @default.
- W70976452 countsByYear W709764522015 @default.
- W70976452 countsByYear W709764522016 @default.
- W70976452 countsByYear W709764522017 @default.
- W70976452 countsByYear W709764522018 @default.
- W70976452 countsByYear W709764522019 @default.
- W70976452 countsByYear W709764522021 @default.
- W70976452 countsByYear W709764522022 @default.
- W70976452 crossrefType "journal-article" @default.
- W70976452 hasAuthorship W70976452A5001066329 @default.
- W70976452 hasAuthorship W70976452A5011806164 @default.
- W70976452 hasAuthorship W70976452A5018621362 @default.
- W70976452 hasAuthorship W70976452A5022712318 @default.
- W70976452 hasAuthorship W70976452A5024202047 @default.
- W70976452 hasAuthorship W70976452A5028056789 @default.
- W70976452 hasAuthorship W70976452A5029816641 @default.
- W70976452 hasAuthorship W70976452A5030393361 @default.
- W70976452 hasAuthorship W70976452A5032050812 @default.
- W70976452 hasAuthorship W70976452A5035626095 @default.
- W70976452 hasAuthorship W70976452A5037169725 @default.
- W70976452 hasAuthorship W70976452A5038841996 @default.
- W70976452 hasAuthorship W70976452A5040001760 @default.
- W70976452 hasAuthorship W70976452A5057678079 @default.
- W70976452 hasAuthorship W70976452A5067126589 @default.
- W70976452 hasAuthorship W70976452A5073947547 @default.
- W70976452 hasAuthorship W70976452A5076109830 @default.
- W70976452 hasAuthorship W70976452A5084414168 @default.
- W70976452 hasAuthorship W70976452A5085057434 @default.
- W70976452 hasAuthorship W70976452A5085264071 @default.
- W70976452 hasAuthorship W70976452A5086181841 @default.
- W70976452 hasConcept C121332964 @default.
- W70976452 hasConcept C121608353 @default.
- W70976452 hasConcept C126322002 @default.
- W70976452 hasConcept C142424586 @default.
- W70976452 hasConcept C143998085 @default.
- W70976452 hasConcept C203092338 @default.
- W70976452 hasConcept C2777408962 @default.
- W70976452 hasConcept C2777701055 @default.
- W70976452 hasConcept C2778020697 @default.
- W70976452 hasConcept C2778461978 @default.
- W70976452 hasConcept C2780007613 @default.
- W70976452 hasConcept C2780850621 @default.
- W70976452 hasConcept C2781107101 @default.
- W70976452 hasConcept C2909962599 @default.
- W70976452 hasConcept C2911091166 @default.
- W70976452 hasConcept C29730261 @default.
- W70976452 hasConcept C31760486 @default.
- W70976452 hasConcept C3875195 @default.
- W70976452 hasConcept C535046627 @default.
- W70976452 hasConcept C71924100 @default.
- W70976452 hasConcept C87355193 @default.
- W70976452 hasConcept C90924648 @default.
- W70976452 hasConceptScore W70976452C121332964 @default.
- W70976452 hasConceptScore W70976452C121608353 @default.
- W70976452 hasConceptScore W70976452C126322002 @default.
- W70976452 hasConceptScore W70976452C142424586 @default.
- W70976452 hasConceptScore W70976452C143998085 @default.
- W70976452 hasConceptScore W70976452C203092338 @default.
- W70976452 hasConceptScore W70976452C2777408962 @default.
- W70976452 hasConceptScore W70976452C2777701055 @default.
- W70976452 hasConceptScore W70976452C2778020697 @default.
- W70976452 hasConceptScore W70976452C2778461978 @default.
- W70976452 hasConceptScore W70976452C2780007613 @default.
- W70976452 hasConceptScore W70976452C2780850621 @default.
- W70976452 hasConceptScore W70976452C2781107101 @default.
- W70976452 hasConceptScore W70976452C2909962599 @default.
- W70976452 hasConceptScore W70976452C2911091166 @default.